Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 196 AL 210

The role of tau kinases in Alzheimer's disease

Dolan PJ, Johnson GV.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):595-603.

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT.

Curr Med Res Opin. 2010 Oct;26(10):2441-7. doi: 10.1185/03007995.2010.513849.

B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review

Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B.

J Alzheimers Dis. 2010;22(1):205-24. doi: 10.3233/JAD-2010-090940.

Decline of human tactile angle discrimination in patients with mild cognitive impairment and Alzheimer's disease

Yang J, Ogasa T, Ohta Y, Abe K, Wu J.

J Alzheimers Dis. 2010;22(1):225-34. doi: 10.3233/JAD-2010-100723.

Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro

Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q.

J Alzheimers Dis. 2010;22(1):257-66. doi: 10.3233/JAD-2010-100684.

[Therapeutic strategies for Alzheimer disease based on endoplasmic reticulum stress]

Kudo T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):163-8.

[Immunotherapy and Alzheimer's disease]

Arai H.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):173-6.

[Drug development for tauopathy and Alzheimer's disease]

Takashima A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80.

Cholinergic central system, Alzheimer's disease, and anesthetics liaison: a vicious circle?

Schifilliti D, Santamaria LB, Rosa G, Di Nino G, Mandal PK, Fodale V.

J Alzheimers Dis. 2010;22 Suppl 3:35-41. doi: 10.3233/JAD-2010-101317.

Transport of drugs across the blood-brain barrier in Alzheimer's disease

Nicolazzo JA, Mehta DC.

Ther Deliv. 2010 Oct;1(4):595-611. doi: 10.4155/tde.10.41.

Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments

McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.

J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.

Developmental exposure to lead and late life abnormalities of nervous system

Basha R, Reddy GR.

Indian J Exp Biol. 2010 Jul;48(7):636-41.

Phenserine efficacy in Alzheimer's disease

Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.

J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.

The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease

Cappell J, Herrmann N, Cornish S, Lanctôt KL.

CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.

Investigational medications for treatment of patients with Alzheimer disease

Potter PE.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias